These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 33119313)

  • 1. Molecular Basis of SARS-CoV-2 Infection and Rational Design of Potential Antiviral Agents: Modeling and Simulation Approaches.
    Francés-Monerris A; Hognon C; Miclot T; García-Iriepa C; Iriepa I; Terenzi A; Grandemange S; Barone G; Marazzi M; Monari A
    J Proteome Res; 2020 Nov; 19(11):4291-4315. PubMed ID: 33119313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In silico study of azithromycin, chloroquine and hydroxychloroquine and their potential mechanisms of action against SARS-CoV-2 infection.
    Braz HLB; Silveira JAM; Marinho AD; de Moraes MEA; Moraes Filho MO; Monteiro HSA; Jorge RJB
    Int J Antimicrob Agents; 2020 Sep; 56(3):106119. PubMed ID: 32738306
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting the SARS-CoV-2 spike glycoprotein prefusion conformation: virtual screening and molecular dynamics simulations applied to the identification of potential fusion inhibitors.
    Romeo A; Iacovelli F; Falconi M
    Virus Res; 2020 Sep; 286():198068. PubMed ID: 32565126
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic antiviral effect of hydroxychloroquine and azithromycin in combination against SARS-CoV-2: What molecular dynamics studies of virus-host interactions reveal.
    Fantini J; Chahinian H; Yahi N
    Int J Antimicrob Agents; 2020 Aug; 56(2):106020. PubMed ID: 32405156
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimization Rules for SARS-CoV-2 M
    Stoddard SV; Stoddard SD; Oelkers BK; Fitts K; Whalum K; Whalum K; Hemphill AD; Manikonda J; Martinez LM; Riley EG; Roof CM; Sarwar N; Thomas DM; Ulmer E; Wallace FE; Pandey P; Roy S
    Viruses; 2020 Aug; 12(9):. PubMed ID: 32859008
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Repurposing of FDA-Approved Toremifene to Treat COVID-19 by Blocking the Spike Glycoprotein and NSP14 of SARS-CoV-2.
    Martin WR; Cheng F
    J Proteome Res; 2020 Nov; 19(11):4670-4677. PubMed ID: 32907334
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A search for medications to treat COVID-19 via in silico molecular docking models of the SARS-CoV-2 spike glycoprotein and 3CL protease.
    Hall DC; Ji HF
    Travel Med Infect Dis; 2020; 35():101646. PubMed ID: 32294562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing.
    Kumar Y; Singh H; Patel CN
    J Infect Public Health; 2020 Sep; 13(9):1210-1223. PubMed ID: 32561274
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Sachdeva C; Wadhwa A; Kumari A; Hussain F; Jha P; Kaushik NK
    OMICS; 2020 Oct; 24(10):568-580. PubMed ID: 32757981
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced Binding of SARS-CoV-2 Spike Protein to Receptor by Distal Polybasic Cleavage Sites.
    Qiao B; Olvera de la Cruz M
    ACS Nano; 2020 Aug; 14(8):10616-10623. PubMed ID: 32806067
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In silico design of antiviral peptides targeting the spike protein of SARS-CoV-2.
    Ling R; Dai Y; Huang B; Huang W; Yu J; Lu X; Jiang Y
    Peptides; 2020 Aug; 130():170328. PubMed ID: 32380200
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In silico ADMET and molecular docking study on searching potential inhibitors from limonoids and triterpenoids for COVID-19.
    Vardhan S; Sahoo SK
    Comput Biol Med; 2020 Sep; 124():103936. PubMed ID: 32738628
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unravelling lead antiviral phytochemicals for the inhibition of SARS-CoV-2 M
    Gurung AB; Ali MA; Lee J; Farah MA; Al-Anazi KM
    Life Sci; 2020 Aug; 255():117831. PubMed ID: 32450166
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular Simulations and Network Modeling Reveal an Allosteric Signaling in the SARS-CoV-2 Spike Proteins.
    Verkhivker GM
    J Proteome Res; 2020 Nov; 19(11):4587-4608. PubMed ID: 33006900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design and Evaluation of Anti-SARS-Coronavirus Agents Based on Molecular Interactions with the Viral Protease.
    Akaji K; Konno H
    Molecules; 2020 Aug; 25(17):. PubMed ID: 32867349
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design of Potent Membrane Fusion Inhibitors against SARS-CoV-2, an Emerging Coronavirus with High Fusogenic Activity.
    Zhu Y; Yu D; Yan H; Chong H; He Y
    J Virol; 2020 Jul; 94(14):. PubMed ID: 32376627
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In Silico Insights into the SARS CoV-2 Main Protease Suggest NADH Endogenous Defences in the Control of the Pandemic Coronavirus Infection.
    Martorana A; Gentile C; Lauria A
    Viruses; 2020 Jul; 12(8):. PubMed ID: 32722574
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Why Are Lopinavir and Ritonavir Effective against the Newly Emerged Coronavirus 2019? Atomistic Insights into the Inhibitory Mechanisms.
    Nutho B; Mahalapbutr P; Hengphasatporn K; Pattaranggoon NC; Simanon N; Shigeta Y; Hannongbua S; Rungrotmongkol T
    Biochemistry; 2020 May; 59(18):1769-1779. PubMed ID: 32293875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A molecular docking study revealed that synthetic peptides induced conformational changes in the structure of SARS-CoV-2 spike glycoprotein, disrupting the interaction with human ACE2 receptor.
    Souza PFN; Lopes FES; Amaral JL; Freitas CDT; Oliveira JTA
    Int J Biol Macromol; 2020 Dec; 164():66-76. PubMed ID: 32693122
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Proteins of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS CoV-2 or n-COV19), the Cause of COVID-19.
    Yoshimoto FK
    Protein J; 2020 Jun; 39(3):198-216. PubMed ID: 32447571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.